Results 181 to 190 of about 107,749 (252)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. [PDF]

Leukemia, 2020
La Rosée F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, La Rosée P.   +10 more
europepmc   +1 more source

Targeting Inflammation and Immune Regulation in Chronic Inflammation Associated Cancers

Cancer Science, EarlyView.
Chronic inflammation sustains activation of key inflammatory pathways, including Nuclear factor kappa B (NF‐κB), Interleukin‐6‐signal transducer and activator of transcription 3 (IL6‐STAT3), Phosphoinositide 3‐kinase/Akt (PI3K/Akt), and Wingless/β‐catenin (Wnt/β‐catenin) signaling. This promotes immune dysregulation through the expansion and functional
Lawan Rabiu, Mengzhu Chinn, Feng Chen, Yerkezhan Yerkinkazhina, Yuan Tian, Wei‐Guo Zhu   +5 more
wiley   +1 more source

Successful treatment of rheumatoid arthritis-associated interstitial lung disease with filgotinib: A case report on janus kinase 1 inhibition. [PDF]

Respirol Case Rep
Sunaga A, Inoue T.
europepmc   +1 more source

Interferon-γ/Janus Kinase 1/STAT1 Signaling Represses Forkhead Box A1 and Drives a Basal Transcriptional State in Muscle-Invasive Bladder Cancer. [PDF]

Am J Pathol
Lawrence SS, Yamashita H, Shuman L, Raman JD, Joshi M, Yochum GS, Wu XR, Al-Ahmadie HA, Warrick JI, Walter V, DeGraff DJ.   +10 more
europepmc   +1 more source

Effect of Delgocitinib Cream on Health‐Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema

Contact Dermatitis, EarlyView.
Patient‐reported outcomes are an important complement to physician‐assessed clinical outcome measures in Chronic Hand Eczema. In a pooled analysis of two randomised, controlled trials, twice‐daily treatment with delgocitinib cream 20 mg/g significantly improved the health‐related quality of life of patients with moderate to severe Chronic Hand Eczema ...
Andrea Bauer, Lyn Guenther, Richard Woolf, Eydna Didriksen Apol, Douglas Maslin, Nanna Nyholm, Henrik Thoning, Marie Louise Schuttelaar   +7 more
wiley   +1 more source

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis. [PDF]

Arthritis Res Ther, 2020
Thudium CS, Bay-Jensen AC, Cahya S, Dow ER, Karsdal MA, Koch AE, Zhang W, Benschop RJ.   +7 more
europepmc   +1 more source

Erosive pustular dermatosis of the lower legs (EPDL): A rarely diagnosed neutrophilic dermatosis of the elderly

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Erosive pustular dermatosis of the lower legs (EPDL) is a rarely diagnosed, chronic inflammatory skin disease that occurs predominantly in elderly people. Predisposing factors include skin atrophy, chronic venous insufficiency, and trauma. Although the pathogenesis of EPDL has not yet been conclusively clarified, there are ongoing discussions ...
Joachim Dissemond, Jan Kottner, Jan‐Malte Placke, Cornelia Erfurt‐Berge   +3 more
wiley   +1 more source

Systematic review and network meta-analysis of the risk of malignancy with biologic therapies and selective Janus kinase-1 inhibitors in atopic dermatitis. [PDF]

Postepy Dermatol Alergol
Manzar D, Nair N, Suntres E, Rodrigues M, Alghanemi L, Abu-Hilal M.   +5 more
europepmc   +1 more source

Systematic review and network meta-analysis of the risk of Herpes zoster with biological therapies and selective Janus kinase-1 inhibitors in atopic dermatitis. [PDF]

Postepy Dermatol Alergol
Manzar D, Nair N, Suntres E, Rodrigues M, Abu-Hilal M.   +4 more
europepmc   +1 more source